Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) priced a firm‑commitment public offering of 2,962,963 shares of common stock and an equal number of warrants at $1.35 each, generating roughly $4.0 million in gross proceeds. Dawson James Securities served as bookrunner and the offering includes a 15% over‑allotment option on both shares and warrants. The transaction is slated to close on April 27 2026, subject to customary closing conditions.
The company’s balance sheet reflects a substantial accumulated deficit and an Altman Z‑score of –19.25, indicating a high probability of financial distress. Market capitalization is in the low‑million range, and Nasdaq compliance issues have previously prompted the company to seek additional liquidity. The net proceeds will be directed toward general corporate purposes, with a focus on working‑capital needs and ongoing product development in the stabilized hypochlorous acid (HOCl) market.
Sonoma’s recent product launches—including an advanced burn‑relief hydrogel in CVS and Walmart and a new dermatology line under the Aquanil brand—illustrate its growth strategy. However, the offering price of $1.35 represents a discount to the current trading price of $1.80 and sits near the 52‑week low of $1.79, underscoring the company’s need to raise capital at a valuation that reflects its financial challenges. The issuance of new shares and warrants will dilute existing shareholders, a typical consequence of such a financing event.
Prior to this filing, a separate announcement on April 23 2026 detailed a different offering structure: $5 million in gross proceeds at $2.47 per unit for 2,024,291 units. The shift to the current terms suggests a rapid adjustment in the company’s financing strategy, likely driven by market conditions and the urgency of securing liquidity.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.